

Translating CLINICAL TRIAL DATA into CLINICAL PRACTICE:

Expert Roundtable Discussion of Management
Considerations in Hematologic Malignancies

A LUNCH SYMPOSIUM DURING THE LYMPHOMA & MYELOMA 2010 CONGRESS

CONTINUING MEDICAL EDUCATION

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum of 1.5 *AMA PRA Category 1 Credits*SM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

OBJECTIVES

After successful completion of this educational activity, attendees should be able to:

- Impact patient outcomes by assimilating the mechanism of action, toxicity, and reported therapeutic response for both current and emerging agents in myeloma
- Determine how investigational regimens can be used in conjunction with currently used treatment regimens (i.e. CHOP-based therapy) and/or stem cell transplantation for aggressive lymphomas
- Evaluate innovative strategies to treat peripheral T-cell lymphoma and how clinical and molecular features of the disease impact the appropriate choice and intensity of therapy
- Maintain clinical responses after disease progression for diffuse large B-cell lymphoma and mantle cell lymphoma using reported clinical data on the impact of novel therapy

SYMPOSIUM REGISTRATION

Registration is complimentary to attendees of the Lymphoma & Myeloma 2010 Congress.

WHO SHOULD ATTEND

This educational activity is intended for clinicians interested in and involved in the care of patients with hematologic malignancies, including community hematologists and oncologists, transplant oncologists, nurse practitioners, oncology nurses, oncology pharmacy specialists, and other allied health professionals.

FACULTY

Myron S. Czuczman, MD
Roswell Park Cancer Institute
Buffalo, New York, United States

Rebecca Elstrom, MD, MA
Weill Cornell Medical College
New York, New York, United States


Ruben Niesvizky, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
The New York Presbyterian Hospital
New York, New York, United States

Owen A. O'Connor, MD, PhD
NYU Cancer Institute
NYU Langone Medical Center
New York, New York, United States

Antonio Palumbo, MD
University of Torino
Torino, Italy

Michael E. Williams, MD
University of Virginia School of Medicine
Charlottesville, Virginia, United States

SYMPOSIUM ORGANIZER

 Imedex[®]
4325 Alexander Drive
Alpharetta, Georgia
30022-3740, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
www.imedex.com

SCIENTIFIC AGENDA

FRIDAY, OCTOBER 22, 2010 // CHAIR: MYRON S. CZUCZMAN, MD

11:45 am	Lunch served	12:45 pm	Peripheral T-cell Lymphoma Case: Determining the optimal therapies for relapsed/refractory PTCL Panel discussant: Owen A. O'Connor, MD, PhD
12:00 pm	Program description and introduction of faculty panel Myron S. Czuczman, MD	1:05 pm	Mantle Cell Lymphoma Case: Achieving and maintaining disease free survival through innovative use of novel agents for replaced MCL Panel discussant: Michael E. Williams, MD
12:05 pm	Multiple Myeloma Case: Achieving long term disease control in frontline Multiple Myeloma Panel Discussants: Antonio Palumbo, MD Ruben Niesvizky, MD	1:25 pm	Panel consensus take-home message for the audience
12:25 pm	Diffuse Large B-cell Lymphoma Case: Incorporation of novel agents after relapse from R-CHOP-based therapy Panel Discussant: Rebecca Elstrom, MD, MA	1:30 pm	Adjourn

OCTOBER 22, 2010
NEW YORK, NEW YORK

Waldorf=Astoria, Starlight Roof



The following company has provided an educational grant in support of this symposium:

CORPORATE SUPPORT

A LUNCH SYMPOSIUM DURING THE LYMPHOMA & MYELOMA 2010 CONGRESS

Expert Roundtable Discussion of Management Considerations in Hematologic Malignancies

Translating CLINICAL TRIAL DATA into CLINICAL PRACTICE:

Translating CLINICAL TRIAL DATA into CLINICAL PRACTICE:

Expert Roundtable Discussion of Management Considerations in Hematologic Malignancies

A LUNCH SYMPOSIUM DURING THE LYMPHOMA & MYELOMA 2010 CONGRESS



SYMPOSIUM CHAIR
Myron S. Czuczman, MD
Roswell Park Cancer Institute
Buffalo, New York, United States